{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:59:59Z","timestamp":1791291599052,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":1651,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","award":["NCT01362296"],"award-info":[{"award-number":["NCT01362296"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1093\/annonc\/mdv072","type":"journal-article","created":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T02:17:54Z","timestamp":1425003474000},"page":"894-901","source":"Crossref","is-referenced-by-count":321,"title":["A randomized phase II study of the MEK1\/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)"],"prefix":"10.1016","volume":"26","author":[{"suffix":"Jr","given":"G.R.","family":"Blumenschein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.-W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"De Pas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dunphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Udud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-J.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.H.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rappold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Redhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Puski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.S.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"J\u00e4nne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv072_bb0010","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv072_bb0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1513\/pats.200809-107LC","article-title":"KRAS mutations in non-small cell lung cancer","volume":"6","author":"Riely","year":"2009","journal-title":"Proc Am Thorac Soc"},{"key":"10.1093\/annonc\/mdv072_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cancergencyto.2010.07.134","article-title":"Somatic mutations of signaling genes in non-small-cell lung cancer","volume":"203","author":"Sanders","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1093\/annonc\/mdv072_bb0025","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1440-1827.2010.02580.x","article-title":"KRAS gene mutations in lung cancer: particulars established and issues unresolved","volume":"60","author":"Okudela","year":"2010","journal-title":"Pathol Int"},{"key":"10.1093\/annonc\/mdv072_bb0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.bjc.6602258","article-title":"The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis","volume":"92","author":"Mascaux","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv072_bb0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/cncr.27730","article-title":"Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas","volume":"119","author":"Johnson","year":"2013","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv072_bb0040","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1200\/JCO.2009.27.4365","article-title":"Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?","volume":"28","author":"Roberts","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv072_bb0045","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","article-title":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","volume":"23","author":"Eberhard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv072_bb0050","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-06-3043","article-title":"KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"13","author":"Massarelli","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv072_bb0055","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1158\/1078-0432.CCR-09-0888","article-title":"Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials","volume":"15","author":"Jackman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv072_bb0060","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1002\/cncr.27637","article-title":"Driver mutations determine survival in smokers and never-smokers with stage IIIB\/IV lung adenocarcinomas","volume":"118","author":"Paik","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv072_bb0065","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.6004\/jnccn.2012.0130","article-title":"Non-small cell lung cancer","volume":"10","author":"Ettinger","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1093\/annonc\/mdv072_bb0070","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/1535-7163.MCT-11-0505","article-title":"Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212","volume":"11","author":"Jing","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdv072_bb0075","unstructured":"LLiuTGilmerHShiPreclinical modeling of susceptibility of NSCLC cells with RAS mutations to GSK1120212, a potent and selective MEK1\/MEK2 inhibitor: implication for clinical development. In: 14th World Conference on Lung Cancer. Abstract MO04.11."},{"key":"10.1093\/annonc\/mdv072_bb0080","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1158\/1538-7445.AM2011-4394","article-title":"Identification of molecular determinants of response to GSK1120212B, a potent and selective MEK inhibitor, as a single agent and in combination in RAS\/RAF mutant nonsmall cell lung carcinoma cells","volume":"71","author":"Liu","year":"2011","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv072_bb0085","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv072_bb0090","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdv072_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv072_bb0100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","article-title":"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study","volume":"14","author":"Janne","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv072_bb0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv072_bb0110","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1200\/jco.2013.31.15_suppl.8026","article-title":"Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations","volume":"31","author":"Carter","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv072_bb0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/annonc\/mdq680","article-title":"Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer","volume":"22","author":"Garassino","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv072_bb0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cancergen.2012.12.003","article-title":"The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer","volume":"206","author":"Fiala","year":"2013","journal-title":"Cancer Genet"},{"key":"10.1093\/annonc\/mdv072_bb0125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jnci\/djr523","article-title":"Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome","volume":"104","author":"Ihle","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv072_bb0130","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/bjc.2012.8","article-title":"The MEK1\/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models","volume":"106","author":"Holt","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv072_bb0135","doi-asserted-by":"crossref","first-page":"8028","DOI":"10.1200\/jco.2013.31.15_suppl.8028","article-title":"Oral MEK1\/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): a phase I\/Ib trial","volume":"31","author":"Gandara","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv072_bb0140","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers","volume":"14","author":"Engelman","year":"2008","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdv072_bb0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccr.2012.11.007","article-title":"Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models","volume":"23","author":"Corcoran","year":"2013","journal-title":"Cancer Cell"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419315145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419315145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/5\/894\/13706190\/mdv072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T17:45:46Z","timestamp":1691430346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419315145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0923753419315145"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv072","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}